Inventor · disambiguated record
Karen S. Gushurst
Also filed as: GUSHURST KAREN S · GUSHURST KAREN SUE
14 granted patents·6 pending applications·213 citations·filing 2002–2016
93Inventor score
Top patents by PatentIndex Score
20 records- 0196US6605729B1Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)WARNER LAMBERT CO·Filed 2002·Granted Aug 12, 2003·104 cites·15 claims
- 0293US8067429B2Forms of rifaximin and uses thereofGUSHURST KAREN S·Filed 2009·Granted Nov 29, 2011·23 cites·23 claims
- 0392US8569326B2Forms of rifaximin and uses thereofGUSHURST KAREN S·Filed 2012·Granted Oct 29, 2013·16 cites·19 claims
- 0490US8486956B2Forms of rifaximin and uses thereofGUSHURST KAREN S·Filed 2010·Granted Jul 16, 2013·13 cites·11 claims
- 0588US9273066B2Forms of rifaximin and uses thereofSALIX PHARMACEUTICALS LTD·Filed 2013·Granted Mar 1, 2016·7 cites·20 claims
- 0686US9034892B2Forms of rifaximin and uses thereofSALIX PHARMACEUTICALS INC·Filed 2013·Granted May 19, 2015·6 cites·20 claims
- 0785US8754098B2Forms of rifaximin and uses thereofGUSHURST KAREN S·Filed 2012·Granted Jun 17, 2014·5 cites·22 claims
- 0884US8466280B2Co-crystal compound of rivaroxaban and malonic acidGRUNENBERG ALFONS·Filed 2009·Granted Jun 18, 2013·18 cites·11 claims
- 0983US9181274B2Forms of rifaximin and uses thereofGUSHURST KAREN S·Filed 2012·Granted Nov 10, 2015·4 cites·7 claims
- 1081US8563571B2Crystalline forms of oxymorphone hydrochlorideGUSHURST KAREN S·Filed 2011·Granted Oct 22, 2013·8 cites·22 claims
- 1180US7144915B2Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)WARNER LAMBERT CO·Filed 2003·Granted Dec 5, 2006·9 cites·46 claims
- 1268US9359357B2Forms of rifaximin and uses thereofGUSHURST KAREN S·Filed 2014·Granted Jun 7, 2016·0 cites·17 claims
- 1365US2008287521A1Crystalline Forms Of [R-(R*,R*)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methyl- Ethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid Calcium Salt (2:1)PFIZER·Filed 2008·Application pending·0 cites
- 1463US2008214651A1Crystalline forms of [R-(R*, R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)PFIZER·Filed 2007·Application pending·0 cites
- 1562US9700545B2Forms of rifaximin and uses thereofSALIX PHARMACEUTICALS LTD·Filed 2016·Granted Jul 11, 2017·0 cites·5 claims
- 1660US9546183B2Forms of rifaximin and uses thereofSALIX PHARMACEUTICALS LTD·Filed 2016·Granted Jan 17, 2017·0 cites·4 claims
- 1757US2012076857A1Forms of rifaximin and uses thereofGUSHURST KAREN S·Filed 2011·Application pending·0 cites
- 1854US2011105550A1Forms of rifaximin and uses thereofSALIX PHARMACEUTICALS LTD·Filed 2010·Application pending·0 cites
- 1948US2008051435A1Crystalline and amorphous forms of tiagabineCEPHALON INC·Filed 2007·Application pending·0 cites
- 2045US2008064727A1Crystalline forms of tiagabine hydrochlorideCEPHALON INC·Filed 2007·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →